Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,728.86
(
0.44%
)
US TECH 100
24,158.20
(
0.60%
)
Dow Jones
47,103.43
(
0.33%
)
Brent Oil
100.57
(
2.30%
)
Bitcoin
74,621.03
(
-0.30%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

pollyvonwog

Send PM Follow Ignore
Followers 20
Posts 2057
Boards Moderated 0
Alias Born 06/14/2007

pollyvonwog

Re: DewDiligence post# 151876

Wednesday, 11/07/2012 12:24:27 PM

Wednesday, November 07, 2012 12:24:27 PM

Post# of 257251

Momenta expects to submit the first IND (Investigational New Drug) application in 2014 for its lead biosimilar, M923



So how will this work exactly? They submit the IND and then the FDA tells them where to go from there I take it? Best case scenario is FDA lets them skip all the trials? Or should we assume at least some degree of trials... Best case scenario, 2016 kind of thing?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now